Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Dasatinib.

¹Division of Hematology/Oncology, UCSF School of Medicine, San Francisco, California 94143, USA. nshah@medicine.ucsf.edu

Drugs of Today (Barcelona, Spain : 1998)

|February 23, 2007

Summary

This summary is machine-generated.

Dasatinib effectively inhibits tyrosine kinases like BCR-ABL, offering a potent alternative for imatinib-resistant leukemia. Clinical studies show significant efficacy without dose-limiting toxicity in chronic myeloid and acute lymphoblastic leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.

Leukemia·2026

Same author

An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition.

Bioorganic chemistry·2026

Same author

Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Hematology (Amsterdam, Netherlands)·2025

Same author

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML.

Archiv der Pharmazie·2025

Same author

How I individualize frontline treatment for chronic-phase CML.

Blood·2025

Same author

Resistance to Allosteric Inhibitors.

Journal of molecular biology·2025

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Dasatinib is a potent oral tyrosine kinase inhibitor targeting ABL and SRC kinases.
Preclinical data indicate dasatinib's superior potency against BCR-ABL compared to imatinib, including imatinib-resistant mutants.

Purpose of the Study:

To evaluate the safety and efficacy of dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
To assess dasatinib's activity in patients resistant or intolerant to imatinib therapy.

Main Methods:

Phase I and II clinical trials were conducted in adult patients with CML and Ph+ ALL.
Dose escalation and expansion cohorts were used to determine safety and efficacy endpoints.

Related Experiment Videos

Main Results:

Dasatinib demonstrated substantial clinical efficacy at doses without observed dose-limiting toxicities.
Phase II studies confirmed Phase I findings, supporting dasatinib's effectiveness in imatinib-resistant/intolerant CML and therapy-resistant Ph+ ALL.

Conclusions:

Dasatinib is an effective treatment option for imatinib-resistant/intolerant CML and therapy-resistant Ph+ ALL.
The drug offers a favorable safety profile with significant clinical benefit in targeted patient populations.